Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

CEO

Dr. Cheng Fang Ph.D.

Employees

Country

ISIN

US03615A1088

Listings

0 Comments

Share your thoughts

FAQ

What is Annovis Bio stock price today?▼

The current price of 07X.STU is €1.35 EUR — it has increased by +0% in the past 24 hours. Watch Annovis Bio stock price performance more closely on the chart.

What is Annovis Bio stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Annovis Bio stocks are traded under the ticker 07X.STU.

How many employees does Annovis Bio have?▼

As of April 10, 2026, the company has 8 employees.

In which sector is Annovis Bio located?▼

Annovis Bio operates in the Health Care sector.

When did Annovis Bio complete a stock split?▼

Annovis Bio has not had any recent stock splits.

Where is Annovis Bio headquartered?▼

Annovis Bio is headquartered in Malvern, US.